Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Advertising and Sponsorship
    • Profile & Readership
    • Contact Us
    • Latest News
    • Privacy & Cookies Policies
    • Terms of Use
    • Advertising Terms
    • Issue 81
    • Issue 80
    • Issue 79
    • Issue 78
    • Issue 77
    • Issue 76
    • Issue 75
    • Issue 74
    • Issue 73
    • Issue 72
    • Issue 71
    • Issue 70
    • View All
    • About the Awards
    • Awards Timetable
    • Awards Winners
    • Submit Nominations
    • Testimonials
    • Media Room
    • FAQ
    • Asset Management Awards
    • Brand of the Year Awards
    • Business Awards
    • Cash Management Banking Awards
    • Banking Technology Awards
    • CEO Awards
    • Customer Service Awards
    • CSR Awards
    • Deal of the Year Awards
    • Corporate Governance Awards
    • Corporate Banking Awards
    • Digital Transformation Awards
    • Fintech Awards
    • Education & Training Awards
    • ESG & Sustainability Awards
    • ESG Awards
    • Forex Banking Awards
    • Innovation Awards
    • Insurance & Takaful Awards
    • Investment Banking Awards
    • Investor Relations Awards
    • Leadership Awards
    • Islamic Banking Awards
    • Real Estate Awards
    • Project Finance Awards
    • Process & Product Awards
    • Telecommunication Awards
    • HR & Recruitment Awards
    • Trade Finance Awards
    • The Next 100 Global Awards
    • Wealth Management Awards
    • Travel Awards
    • Years of Excellence Awards
    • Publishing Principles
    • Ownership & Funding
    • Corrections Policy
    • Editorial Code of Ethics
    • Diversity & Inclusion Policy
    • Fact Checking Policy
    Original content: Global Banking and Finance Review - https://www.globalbankingandfinance.com

    A global financial intelligence and recognition platform delivering authoritative insights, data-driven analysis, and institutional benchmarking across Banking, Capital Markets, Investment, Technology, and Financial Infrastructure.

    Copyright © 2010-2026 - All Rights Reserved. | Sitemap | Tags

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    1. Home
    2. >Finance
    3. >Samsung Biologics to buy US drug production facility from GSK for $280 million
    Finance

    Samsung Biologics to Buy US Drug Production Facility From Gsk for $280 Million

    Published by Global Banking & Finance Review®

    Posted on December 21, 2025

    1 min read

    Last updated: January 20, 2026

    Add as preferred source on Google
    Samsung Biologics to buy US drug production facility from GSK for $280 million - Finance news and analysis from Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Tags:investmentacquisition

    Quick Summary

    Samsung Biologics is acquiring a US drug facility from GSK for $280M to expand capacity and meet US demand, with the deal closing by Q1 2026.

    Samsung Biologics Acquires GSK's US Drug Facility for $280M

    SEOUL, Dec 22 (Reuters) - South Korea's Samsung Biologics said on Monday it is acquiring its first U.S. drug production facility from GSK for $280 million to respond to long-term U.S. market demand.

    The company's U.S. unit, Samsung Biologics America, is acquiring a 100% stake in Human Genome Sciences Inc of Rockville, Maryland, the South Korean contract drug manufacturer said in a statement.

    Samsung Biologics plans additional investments to expand the site's capacity, currently a combined 60,000 liters of drug substance capacity, and to upgrade technology, it said.

    It added that the acquisition value may change when the deal closes, likely around the end of the first quarter of 2026.

    South Korea's Celltrion is also planning to produce drugs in the United States, where the Trump administration has threatened to levy tariffs on pharmaceuticals.

    Under a deal with the United States, tariffs on U.S. imports of South Korean pharmaceuticals will be no greater than 15%, while generic drugs will be tariff-free.

    Samsung Biologics shares were down 0.4% on Monday, lagging the wider market's 2% gain.

    (Reporting by Joyce Lee and Hyunjoo Jin; Editing by Diane Craft and Edmund Klamann)

    Key Takeaways

    • •Samsung Biologics is buying a US facility from GSK for $280 million.
    • •The acquisition aims to meet long-term US market demand.
    • •Samsung Biologics plans to expand and upgrade the facility.
    • •The deal is expected to close by the end of Q1 2026.
    • •Tariffs on South Korean pharmaceuticals in the US will be no greater than 15%.

    Frequently Asked Questions about Samsung Biologics to buy US drug production facility from GSK for $280 million

    1What is an acquisition?

    An acquisition is a corporate action in which one company purchases most or all of another company's shares to gain control of that company.

    2What is biotechnology?

    Biotechnology is a field that uses biological systems, living organisms, or derivatives to develop or create products, often in pharmaceuticals and agriculture.

    3
    What is market demand?

    Market demand refers to the total quantity of a product or service that consumers are willing and able to purchase at a given price over a specific period.

    4What is drug production capacity?

    Drug production capacity is the maximum amount of pharmaceutical products that a manufacturing facility can produce within a specific timeframe.

    More from Finance

    Explore more articles in the Finance category

    Image for Labubu maker Pop Mart meets 2025 revenue expectations
    Labubu Maker Pop Mart Meets 2025 Revenue Expectations
    Image for Israel strikes Tehran as Trump says US negotiating to end war
    Israel Strikes Tehran as Trump Says US Negotiating to End War
    Image for South Korea, Germany exposed to rare earths shortage, Australia's Arafura says
    South Korea, Germany Exposed to Rare Earths Shortage, Australia's Arafura Says
    Image for Currency markets drift as traders sceptical of US efforts to end Iran war
    Currency Markets Drift as Traders Sceptical of US Efforts to End Iran War
    Image for Stocks bounce and oil retreats on Mideast ceasefire reports
    Stocks Bounce and Oil Retreats on Mideast Ceasefire Reports
    Image for Equinor CEO says EU unlikely to increase Russian gas imports
    Equinor CEO Says EU Unlikely to Increase Russian Gas Imports
    Image for Openreach taps Google AI to speed fibre rollout, cut emissions
    Openreach Taps Google AI to Speed Fibre Rollout, Cut Emissions
    Image for UK consumer sentiment falls as Iran war rages, KPMG says
    UK Consumer Sentiment Falls as Iran War Rages, Kpmg Says
    Image for US oil prices fall on prospect of Middle East ceasefire easing supply disruption
    US Oil Prices Fall on Prospect of Middle East Ceasefire Easing Supply Disruption
    Image for Lamborghinis stranded in Sri Lanka as war disrupts Asia's used-car trade 
    Lamborghinis Stranded in Sri Lanka as War Disrupts Asia's Used-Car Trade 
    Image for Britain pilots social media bans, time limits and curfews for children
    Britain Pilots Social Media Bans, Time Limits and Curfews for Children
    Image for UK's Starmer, Saudi crown prince discussed ongoing Middle East conflict, Downing Street says
    UK's Starmer, Saudi Crown Prince Discussed Ongoing Middle East Conflict, Downing Street Says
    View All Finance Posts
    Previous Finance PostJapan's Yen Rises vs Dollar on Intervention Hints; US Dollar Slumps
    Next Finance PostSeatrium, Maersk Settle Dispute Over $475 Million Contract for Offshore Wind Vessel